The growing sophistication of tumor molecular profiling has helped to slowly transition oncologic care toward a more personalized approach in different tumor types, including in bladder cancer. The ...

Trial findings show long-term recurrence-free survival in patients with low-grade upper tract urothelial cancer treated with ...

Targeted Next-Generation Sequencing in Succinate Dehydrogenase–Deficient GI Stromal Tumor Identifies Actionable Alterations in the PI3K/mTOR Pathway This study included 82 patients with ...

Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva.

Adenomatous polyps typically do not cause symptoms unless they progress to colon cancer. Even then, there may be no sign of a problem until the malignancy is advanced. This is why colon cancer ...

UGN-101 showed a 68% three-year RFS rate in low-grade UTUC patients, with a median follow-up of 23.5 months. Maintenance therapy significantly improved RFS, but further studies are needed to confirm ...

Frequent colorectal polyp diagnoses in first- and second-degree relatives are associated with an increased risk for colorectal cancer (CRC), especially early-onset CRC. Researchers evaluated the ...

Meaning, how deep do we think the tumor goes in the bladder? Do we think that there's cancer in the lymph ... Those of us who take care of patients with plasmacytoid urothelial cancer know this ...

Beware of fake cancer drugs that have found their way into the booming online business of counterfeit prescription ...

The frequency of polyp diagnoses in close relatives was strongly associated with colorectal cancer risk. Polyp history in second-degree relatives was only influential with multiple polyp diagnoses.

According to GlobalData, Phase II drugs for Metastatic Transitional (Urothelial) Tract Cancer have a 46% phase transition success rate ... metastatic colorectal cancer, salivary gland tumor, head and ...

Detailed price information for Corbus Pharmaceuticals Hldgs Inc (CRBP-Q) from The Globe and Mail including charting and trades.